Cover Image

Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: results from the SAL-MODULE phase I study

We conducted a phase I trial in newly diagnosed acute myeloid leukaemia (AML) to investigate the combination of two novel targeted agents, gemtuzumab ozogamicin (GO) and midostaurin, with intensive chemotherapy in FLT3-mutated AML and CBF leukaemia. Three dose levels of midostaurin and one to three...

Full description

Saved in:
Bibliographic Details
Main Authors: Röllig, Christoph (Author) , Schliemann, Christoph (Author) , Ruhnke, Leo (Author) , Fransecky, Lars (Author) , Heydrich, Björn-Niklas (Author) , Hanoun, Maher (Author) , Noppeney, Richard (Author) , Schäfer-Eckart, Kerstin (Author) , Wendelin, Knut (Author) , Mikesch, Jan-Henrik (Author) , Middeke, Jan Moritz (Author) , Reimann, Manja (Author) , Fiebig, Frank (Author) , Zukunft, Sven (Author) , Wermke, Martin (Author) , Serve, Hubert (Author) , Platzbecker, Uwe (Author) , Müller-Tidow, Carsten (Author) , Baldus, Claudia D. (Author) , Bornhäuser, Martin (Author)
Format: Article (Journal)
Language:English
Published: June 2024
In: British journal of haematology
Year: 2024, Volume: 204, Issue: 6, Pages: 2254-2258
ISSN:1365-2141
DOI:10.1111/bjh.19436
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/bjh.19436
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.19436
Get full text
Author Notes:Christoph Röllig, Christoph Schliemann, Leo Ruhnke, Lars Fransecky, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Kerstin Schäfer-Eckart, Knut Wendelin, Jan-Henrik Mikesch, Jan Moritz Middeke, Manja Reimann, Frank Fiebig, Sven Zukunft, Martin Wermke, Hubert Serve, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D. Baldus, Martin Bornhäuser

MARC

LEADER 00000caa a2200000 c 4500
001 1904168477
003 DE-627
005 20241205175331.0
007 cr uuu---uuuuu
008 241002s2024 xx |||||o 00| ||eng c
024 7 |a 10.1111/bjh.19436  |2 doi 
035 |a (DE-627)1904168477 
035 |a (DE-599)KXP1904168477 
035 |a (OCoLC)1475314219 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Röllig, Christoph  |d 1971-  |e VerfasserIn  |0 (DE-588)122493168  |0 (DE-627)705929116  |0 (DE-576)293296049  |4 aut 
245 1 0 |a Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML  |b results from the SAL-MODULE phase I study  |c Christoph Röllig, Christoph Schliemann, Leo Ruhnke, Lars Fransecky, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Kerstin Schäfer-Eckart, Knut Wendelin, Jan-Henrik Mikesch, Jan Moritz Middeke, Manja Reimann, Frank Fiebig, Sven Zukunft, Martin Wermke, Hubert Serve, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D. Baldus, Martin Bornhäuser 
264 1 |c June 2024 
300 |b Illustrationen 
300 |a 5 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Veröffentlicht: 09 April 2024 
500 |a Gesehen am 02.10.2024 
520 |a We conducted a phase I trial in newly diagnosed acute myeloid leukaemia (AML) to investigate the combination of two novel targeted agents, gemtuzumab ozogamicin (GO) and midostaurin, with intensive chemotherapy in FLT3-mutated AML and CBF leukaemia. Three dose levels of midostaurin and one to three sequential doses of 3 mg/m2 GO in combination with ‘7 + 3’ induction were evaluated. Based on safety findings in 12 patients, our results show that 3 mg/m2 GO on Days 1 + 4 and 100 mg midostaurin on Days 8-21 can be safely combined with IC in newly diagnosed AML. 
650 4 |a AML 
650 4 |a gemtuzumab ozogamicin 
650 4 |a induction therapy 
650 4 |a intensive therapy 
650 4 |a midostaurin 
700 1 |a Schliemann, Christoph  |e VerfasserIn  |4 aut 
700 1 |a Ruhnke, Leo  |e VerfasserIn  |4 aut 
700 1 |a Fransecky, Lars  |e VerfasserIn  |4 aut 
700 1 |a Heydrich, Björn-Niklas  |e VerfasserIn  |4 aut 
700 1 |a Hanoun, Maher  |e VerfasserIn  |4 aut 
700 1 |a Noppeney, Richard  |e VerfasserIn  |4 aut 
700 1 |a Schäfer-Eckart, Kerstin  |e VerfasserIn  |4 aut 
700 1 |a Wendelin, Knut  |e VerfasserIn  |4 aut 
700 1 |a Mikesch, Jan-Henrik  |e VerfasserIn  |4 aut 
700 1 |a Middeke, Jan Moritz  |e VerfasserIn  |4 aut 
700 1 |a Reimann, Manja  |e VerfasserIn  |4 aut 
700 1 |a Fiebig, Frank  |e VerfasserIn  |4 aut 
700 1 |a Zukunft, Sven  |e VerfasserIn  |4 aut 
700 1 |a Wermke, Martin  |e VerfasserIn  |4 aut 
700 1 |a Serve, Hubert  |e VerfasserIn  |4 aut 
700 1 |a Platzbecker, Uwe  |e VerfasserIn  |4 aut 
700 1 |a Müller-Tidow, Carsten  |d 1968-  |e VerfasserIn  |0 (DE-588)1015101798  |0 (DE-627)705330230  |0 (DE-576)351197893  |4 aut 
700 1 |a Baldus, Claudia D.  |e VerfasserIn  |4 aut 
700 1 |a Bornhäuser, Martin  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t British journal of haematology  |d Oxford [u.a.] : Wiley-Blackwell, 1955  |g 204(2024), 6 vom: Juni, Seite 2254-2258  |h Online-Ressource  |w (DE-627)269758941  |w (DE-600)1475751-5  |w (DE-576)09113997X  |x 1365-2141  |7 nnas  |a Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML results from the SAL-MODULE phase I study 
773 1 8 |g volume:204  |g year:2024  |g number:6  |g month:06  |g pages:2254-2258  |g extent:5  |a Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML results from the SAL-MODULE phase I study 
856 4 0 |u https://doi.org/10.1111/bjh.19436  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.19436  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20241002 
993 |a Article 
994 |a 2024 
998 |g 1015101798  |a Müller-Tidow, Carsten  |m 1015101798:Müller-Tidow, Carsten  |d 910000  |d 910100  |e 910000PM1015101798  |e 910100PM1015101798  |k 0/910000/  |k 1/910000/910100/  |p 18 
999 |a KXP-PPN1904168477  |e 4586083484 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Veröffentlicht: 09 April 2024","Gesehen am 02.10.2024"],"relHost":[{"pubHistory":["1.1955 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"the official journal of the British Society of Haematology"},{"title":"BJH ; the official journal of the British Society for Haematology"}],"language":["eng"],"disp":"Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML results from the SAL-MODULE phase I studyBritish journal of haematology","recId":"269758941","note":["Gesehen am 08.05.08"],"id":{"issn":["1365-2141"],"doi":["10.1111/(ISSN)1365-2141"],"zdb":["1475751-5"],"eki":["269758941"]},"part":{"extent":"5","issue":"6","year":"2024","pages":"2254-2258","text":"204(2024), 6 vom: Juni, Seite 2254-2258","volume":"204"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"BJHaem : an official journal of the British Society for Haematology","title_sort":"British journal of haematology","title":"British journal of haematology"}],"name":{"displayForm":["ed. R. B. Thompson [u.a.]"]},"origin":[{"publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]","dateIssuedKey":"1955","dateIssuedDisp":"1955-","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell"}],"corporate":[{"role":"isb","display":"British Society for Haematology"},{"role":"isb","display":"European Hematology Association"}]}],"id":{"eki":["1904168477"],"doi":["10.1111/bjh.19436"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"noteIll":"Illustrationen","extent":"5 S."}],"title":[{"title":"Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML","title_sort":"Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML","subtitle":"results from the SAL-MODULE phase I study"}],"language":["eng"],"name":{"displayForm":["Christoph Röllig, Christoph Schliemann, Leo Ruhnke, Lars Fransecky, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Kerstin Schäfer-Eckart, Knut Wendelin, Jan-Henrik Mikesch, Jan Moritz Middeke, Manja Reimann, Frank Fiebig, Sven Zukunft, Martin Wermke, Hubert Serve, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D. Baldus, Martin Bornhäuser"]},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"June 2024"}],"recId":"1904168477","person":[{"family":"Röllig","display":"Röllig, Christoph","given":"Christoph","role":"aut"},{"role":"aut","family":"Schliemann","display":"Schliemann, Christoph","given":"Christoph"},{"role":"aut","family":"Ruhnke","display":"Ruhnke, Leo","given":"Leo"},{"role":"aut","family":"Fransecky","display":"Fransecky, Lars","given":"Lars"},{"family":"Heydrich","given":"Björn-Niklas","display":"Heydrich, Björn-Niklas","role":"aut"},{"role":"aut","display":"Hanoun, Maher","given":"Maher","family":"Hanoun"},{"family":"Noppeney","display":"Noppeney, Richard","given":"Richard","role":"aut"},{"role":"aut","family":"Schäfer-Eckart","given":"Kerstin","display":"Schäfer-Eckart, Kerstin"},{"family":"Wendelin","given":"Knut","display":"Wendelin, Knut","role":"aut"},{"role":"aut","display":"Mikesch, Jan-Henrik","given":"Jan-Henrik","family":"Mikesch"},{"role":"aut","family":"Middeke","display":"Middeke, Jan Moritz","given":"Jan Moritz"},{"family":"Reimann","display":"Reimann, Manja","given":"Manja","role":"aut"},{"display":"Fiebig, Frank","given":"Frank","family":"Fiebig","role":"aut"},{"display":"Zukunft, Sven","given":"Sven","family":"Zukunft","role":"aut"},{"family":"Wermke","display":"Wermke, Martin","given":"Martin","role":"aut"},{"role":"aut","family":"Serve","given":"Hubert","display":"Serve, Hubert"},{"given":"Uwe","display":"Platzbecker, Uwe","family":"Platzbecker","role":"aut"},{"role":"aut","given":"Carsten","display":"Müller-Tidow, Carsten","family":"Müller-Tidow"},{"role":"aut","display":"Baldus, Claudia D.","given":"Claudia D.","family":"Baldus"},{"role":"aut","family":"Bornhäuser","display":"Bornhäuser, Martin","given":"Martin"}]} 
SRT |a ROELLIGCHRGEMTUZUMAB2024 

Similar Items